ArticleMaterials today. Bio2026

A transdermal CRISPR/Cas9 strategy using biodegradable microneedles to target YB-1 in melanoma.

Xiazhou Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.